Gessel has advised Bioceltix on a non-brokered public offering of shares carried out under an accelerated book-building procedure and the related private placement.
The total value of the public offering and the private placement amounted to PLN 25.9 million.
Bioceltix is a Wroclaw-headquartered company that develops therapies in veterinary medicine.
According to Gessel, “the public offering included 400,000 new issue series K shares and 150,000 existing shares of the company, admitted to trading on the regulated market of the WSE, offered by its shareholder, Kvarko Group ASI. The public offering was targeted at qualified investors and selected retail investors. As part of the private placement, the company issued 150,000 series L shares, which were subscribed for by Kvarko Group ASI in order to reinvest the funds raised from the sale of the company’s shares in the public offering.”
Back in 2022, Gessel advised Bioceltix on its transition from the NewConnect market to the WSE regulated market (as reported by CEE Legal Matters on September 5, 2022).
The Gessel team included Partner Krzysztof Marczuk, Managing Associate Michal Wielinski, Senior Associate Jakub Rowicki, and Associate Michal Dunikowski.